| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Ceapro Inc (OTCQX: CRPOF)
CRPOF Technical Analysis
3
| As on 9th Jun 2023 CRPOF STOCK Price closed @ 0.40 and we RECOMMEND Sell for LONG-TERM with Stoploss of 0.46 & Sell for SHORT-TERM with Stoploss of 0.41 we also expect STOCK to react on Following IMPORTANT LEVELS. |
CRPOFSTOCK Price
| Open | 0.38 | Change | Price | % |
| High | 0.40 | 1 Day | 0.02 | 5.26 |
| Low | 0.38 | 1 Week | 0.07 | 21.21 |
| Close | 0.40 | 1 Month | -0.02 | -4.76 |
| Volume | 15300 | 1 Year | -0.06 | -13.04 |
| 52 Week High 0.60 | 52 Week Low 0.32 | ||||
OTCQX USA Most Active Stocks
| OREAF | 0.02 | -71.43% |
| RHHBY | 39.15 | -0.63% |
| GBTC | 13.54 | -2.24% |
| ETHE | 7.80 | -2.99% |
| EMHTF | 0.04 | 33.33% |
| VYGVF | 0.15 | -6.25% |
| ZNOG | 0.08 | 14.29% |
| DANOY | 11.58 | -2.11% |
| LGDTF | 0.31 | -3.12% |
| CURLF | 2.96 | -1.33% |
OTCQX USA Top Gainers Stocks
OTCQX USA Top Losers Stocks
| CRPOF Daily Charts |
CRPOF Intraday Charts |
Whats New @ Bazaartrend |
CRPOF Free Analysis |
|
|
CRPOF Important Levels Intraday
| RESISTANCE | 0.44 |
| RESISTANCE | 0.43 |
| RESISTANCE | 0.42 |
| RESISTANCE | 0.41 |
| SUPPORT | 0.39 |
| SUPPORT | 0.38 |
| SUPPORT | 0.37 |
| SUPPORT | 0.36 |
CRPOF Forecast May 2024
| 4th UP Forecast | 0.63 |
| 3rd UP Forecast | 0.56 |
| 2nd UP Forecast | 0.51 |
| 1st UP Forecast | 0.47 |
| 1st DOWN Forecast | 0.33 |
| 2nd DOWN Forecast | 0.29 |
| 3rd DOWN Forecast | 0.24 |
| 4th DOWN Forecast | 0.17 |
CRPOF Weekly Forecast
| 4th UP Forecast | 0.48 |
| 3rd UP Forecast | 0.45 |
| 2nd UP Forecast | 0.44 |
| 1st UP Forecast | 0.42 |
| 1st DOWN Forecast | 0.38 |
| 2nd DOWN Forecast | 0.36 |
| 3rd DOWN Forecast | 0.35 |
| 4th DOWN Forecast | 0.32 |
CRPOF Forecast2024
| 4th UP Forecast | 0.96 |
| 3rd UP Forecast | 0.78 |
| 2nd UP Forecast | 0.67 |
| 1st UP Forecast | 0.56 |
| 1st DOWN Forecast | 0.24 |
| 2nd DOWN Forecast | 0.13 |
| 3rd DOWN Forecast | 0.02 |
| 4th DOWN Forecast | -0.16 |
Ceapro Inc ( OTCQX USA Symbol : CRPOF )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
CRPOF Business Profile
Ceapro Inc., a biotechnology company, engages in the development and commercialization of active ingredients in the United States, Germany, China, Canada, and internationally. It operates in two segments, The Active Ingredient Product Technology Industry and The Cosmeceutical Industry. The company is involved in the development and application of technology to the production of extracts and active ingredients from oats and other renewable plant resources. It adds value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The company's products include natural active ingredients comprising beta glucan, avenanthramides, oat powder, oat oil, oat peptides, and lupin peptides that are marketed to personal care, cosmetic, medical, and animal health industries through its distribution partners and direct sales; natural anti-aging skincare products; and veterinary therapeutic products, such as oat shampoos, ear cleansers, and dermal complexes/conditioners. Its products and technologies that are under research and development, or pre-commercial stage comprise a platform using its beta glucan formulations to deliver compounds for treatments in the personal and healthcare sectors; various novel enabling technologies, such as Pressurized Gas eXpanded drying technology; and technologies to enhance the content of avenanthramides. The company has a collaboration with the McMaster University to develop inhalable therapeutic for COVID-19; a research project with the University of Alberta to expand the utilization of the PGX technology and generate ingredients targeting applications in functional food, dietary supplement, personal care, and pharmaceuticals; a research collaboration with Montreal Heart Institute for clinical study evaluating avenanthramide; and a research collaboration with Angiogenesis Foundation. Ceapro Inc. was incorporated in 1997 and is headquartered in Edmonton, Canada. Address: 7824 ? 51 Avenue NW, Edmonton, AB, Canada, T6E 6W2
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service